These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 28304215)

  • 21. Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation.
    Kuemmel C; Yang Y; Zhang X; Florian J; Zhu H; Tegenge M; Huang SM; Wang Y; Morrison T; Zineh I
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):21-28. PubMed ID: 31652029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translational PK/PD modeling to increase probability of success in drug discovery and early development.
    Lavé T; Caruso A; Parrott N; Walz A
    Drug Discov Today Technol; 2016; 21-22():27-34. PubMed ID: 27978984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians.
    Quartey G; Wang J
    Pharm Stat; 2012; 11(1):82-5. PubMed ID: 21997832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leveraging model-informed approaches for drug discovery and development in the cardiovascular space.
    Dockendorf MF; Vargo RC; Gheyas F; Chain ASY; Chatterjee MS; Wenning LA
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):355-364. PubMed ID: 29353335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactive visualization and communication for increased impact of pharmacometrics.
    Krause A; Gieschke R
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):140S-145S. PubMed ID: 20881227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The utility of modeling and simulation in drug development and regulatory review.
    Huang SM; Abernethy DR; Wang Y; Zhao P; Zineh I
    J Pharm Sci; 2013 Sep; 102(9):2912-23. PubMed ID: 23712632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacometrics, Physiologically Based Pharmacokinetics, Quantitative Systems Pharmacology-What's Next?-Joining Mechanistic and Epidemiological Approaches.
    Schmidt S; Kim S; Vozmediano V; Cristofoletti R; Winterstein AG; Brown JD
    CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):352-355. PubMed ID: 31179639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A review.
    Palmer ME; Andrews LJ; Abbey TC; Dahlquist AE; Wenzler E
    Front Pharmacol; 2022; 13():888079. PubMed ID: 35959440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet.
    Helmlinger G; Al-Huniti N; Aksenov S; Peskov K; Hallow KM; Chu L; Boulton D; Eriksson U; Hamrén B; Lambert C; Masson E; Tomkinson H; Stanski D
    Eur J Pharm Sci; 2017 Nov; 109S():S39-S46. PubMed ID: 28506868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.
    Bhattaram VA; Booth BP; Ramchandani RP; Beasley BN; Wang Y; Tandon V; Duan JZ; Baweja RK; Marroum PJ; Uppoor RS; Rahman NA; Sahajwalla CG; Powell JR; Mehta MU; Gobburu JV
    AAPS J; 2005 Oct; 7(3):E503-12. PubMed ID: 16353928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
    Carroll KJ
    J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.
    Buil-Bruna N; López-Picazo JM; Martín-Algarra S; Trocóniz IF
    Oncologist; 2016 Feb; 21(2):220-32. PubMed ID: 26668254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling the genetic etiology of pharmacokinetic-pharmacodynamic links with the ARMA process.
    Lin M; Berg A; Wu R
    J Biopharm Stat; 2010 Mar; 20(2):351-72. PubMed ID: 20309763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applying dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task force.
    Marshall DA; Burgos-Liz L; IJzerman MJ; Osgood ND; Padula WV; Higashi MK; Wong PK; Pasupathy KS; Crown W
    Value Health; 2015 Jan; 18(1):5-16. PubMed ID: 25595229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of physiologically based pharmacokinetic modeling and simulation in drug development.
    Shardlow CE; Generaux GT; Patel AH; Tai G; Tran T; Bloomer JC
    Drug Metab Dispos; 2013 Dec; 41(12):1994-2003. PubMed ID: 24009310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian approaches in pharmacokinetic decision making.
    Schumacher GE; Barr JT
    Clin Pharm; 1984; 3(5):525-30. PubMed ID: 6488735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force.
    Marshall DA; Burgos-Liz L; IJzerman MJ; Crown W; Padula WV; Wong PK; Pasupathy KS; Higashi MK; Osgood ND;
    Value Health; 2015 Mar; 18(2):147-60. PubMed ID: 25773550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.